Epidarex Portfolio News

15 Oct

28

Enterprise Therapeutics awarded up to £5.7M ($7M) from Cystic Fibrosis Foundation to Support Clinical Development of Novel Chloride Channel Modulator

In All, Portfolio

Support for clinical development up to end of Phase 2 for ETD002, first-in-class TMEM16A potentiator for the treatment of all cystic fibrosis patients Milestone Funding through Cystic Fibrosis Foundation’s Therapeutics Development Award programme Brighton, UK, 15 October 2019: Enterprise Therapeutics Ltd (Enterprise), a biopharmaceutical company…

18 Sep

32

Phase 2 Study Published in Ophthalmology Highlights Efficacy and Safety Data of Intravitreal APL-2 for Geographic Atrophy Secondary to Age-Related Macular Degeneration

In All, Portfolio

CRESTWOOD, Ky. and WALTHAM, Mass., – Apellis Pharmaceuticals Inc., (Nasdaq:APLS) a clinical-stage biopharmaceutical company focused on the development of novel therapeutic compounds to treat disease through the inhibition of the complement system, today announced details about its Phase 2 FILLY study investigating intravitreal (IVT) APL-2 (pegcetacoplan)…

03 Sep

25

Apellis Dosed First Patient in Phase 3 Study of APL-2 for Treatment-Naïve Patients with Paroxysmal Nocturnal Hemoglobinuria

In All, Portfolio

CRESTWOOD, Ky. and WALTHAM, Mass., – Apellis Pharmaceuticals Inc., (Nasdaq:APLS) announced today the dosing of the first patient in the Phase 3 clinical study PRINCE (APL2-308), evaluating the efficacy and safety of APL-2 for treatment-naïve patients with paroxysmal nocturnal hemoglobinuria (PNH). PRINCE is the second Phase…

29 Aug

36

LifeArc Seed Fund Makes £1.5million Investment in Caldan Therapeutics to Develop Novel Treatments for Metabolic Diseases

In All, Portfolio

LifeArc, a UK-based medical research charity, announced today it is investing £1.5million into Caldan Therapeutics Limited, a company developing novel therapeutics for the treatment of metabolic diseases based on original work. Focusing on activators of free fatty acid receptors (GPR120) implicated in the development of…

22 Jul

21

Apellis Pharmaceuticals Expands Leadership Team, Appoints Lucia Celona as Chief People Officer

In All, Portfolio

CRESTWOOD, Ky. and WALTHAM, Mass., – Apellis Pharmaceuticals Inc., (Nasdaq:APLS) a clinical-stage biopharmaceutical company focused on the development of novel therapeutic compounds to treat disease through the inhibition of the complement system, announced today the appointment of Lucia Celona as Chief People Officer. Prior to…

18 Jul

27

Apellis Pharmaceuticals Will Commence APL-9 Program to Control the Complement System in Host Responses to AAV Vector Administration for Gene Therapies

In All, Portfolio

CRESTWOOD, Ky. and WALTHAM, Mass., – Apellis Pharmaceuticals Inc., (Nasdaq:APLS) a clinical-stage biopharmaceutical company focused on the development of novel therapeutic compounds to treat disease through the control of the complement system, today announced its plans to develop APL-9 for the prevention of complement immune…

27 Jun

22

Apellis Pharmaceuticals Completes Enrollment of Phase 3 APL-2 (pegcetacoplan) Head-to-Head Study in Patients with Paroxysmal Nocturnal Hemoglobinuria Treated with Eculizumab

In All, Portfolio

Top-line Data Anticipated in December 2019 CRESTWOOD, Ky. and WALTHAM Mass., June 27, 2019 (GLOBE NEWSWIRE) — Apellis Pharmaceuticals Inc., (Nasdaq:APLS) a clinical-stage biopharmaceutical company focused on the development of novel therapeutic compounds to treat disease through the inhibition of the complement system, today announced the…

10 Apr

23

NodThera Highlights Significant Progress with Advancement of Lead Development Candidate and Key Additions to Board

In All, Portfolio

Company advances NT-0167 as first development candidate from a broad platform of NLRP3 inflammasome inhibitors Appoints Don Nicholson as Board Chairman and Kevin Lee as Independent Director Cambridge, UK, Boston and Seattle – April 10th, 2019 – NodThera, a biotechnology company developing a new class…